|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Strollo SE, Fallon EA, Gapstur SM and
Smith TG: Cancer-related problems, sleep quality, and sleep
disturbance among long-term cancer survivors at 9-years post
diagnosis. Sleep Med. 65:177–185. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tripathy D: Overview: Gemcitabine as
single agent therapy for advanced breast cancer. Clin Breast
Cancer. 3 (Suppl 1):8–11. 2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Heinemann V: Role of gemcitabine in the
treatment of advanced and metastatic breast cancer. Oncology.
64:191–206. 2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hernandez-Aya LF and Ma CX: Chemotherapy
principles of managing stage IV breast cancer in the United States.
Chin Clin Oncol. 5:1–15. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Blackstein M, Vogel CL, Ambinder R, Cowan
J, Iglesias J and Melemed A: Gemcitabin as first line therapy in
patient with metastatic breast cancer: A phase II trail. Oncology.
62:2–8. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu
Y, Shi J, Sun X, Liu Y, Ding Y and Zhao L: MicroRNA-187, a
downstream effector of TGF beta pathway, suppresses Smad-mediated
epithelial-mesenchymal transition in colorectal cancer. Cancer
Lett. 373:203–213. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y,
Fan S and Liu Y: MicroRNA-187, down-regulated in clear cell renal
cell carcinoma and associated with lower survival, inhibits cell
growth and migration though targeting B7-H3. Biochem Biophys Res
Commun. 438:439–444. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Casanova-Salas I, Masiá E, Armiñán A,
Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ
and López-Guerrero JA: MiR-187 targets the androgen-regulated gene
ALDH1A3 in prostate cancer. PLoS One. 10(e0125576)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F
and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer
(NSCLC) development through down-regulation of BCL6. Biochem
Biophys Res Commun. 471:82–88. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mulrane L, Madden SF, Brennan DJ, Gremel
G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG,
et al: Mir-187 is an independent prognostic factor in breast cancer
and confers increased invasive potential in vitro. Clin Cancer Res.
18:6702–6713. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y,
Romero M, Leboeuf C, Janin A, Chen SJ, Wang L and Zhao WL:
MicroRNA187 overexpression is related to tumor progression and
determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Leukemia. 28:880–887. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Turner N and Grose R: Fibroblast growth
factor signaling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Grose R and Dickson C: Fibroblast growth
factor signaling in tumorigenesis. Cytokine Growth Factor Rev.
16:179–186. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ornitz DM and Itoh N: Fibroblast growth
factors. Genome Biol. 2(REVIEWS 3005)2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fillmore CM, Gupta PB, Rudnick JA,
Caballero S, Keller PJ, Lander ES and Kuperwasser C: Estrogen
expands breast cancer stem-like cells through paracrine FGF/Tbx3
signaling. Proc Natl Acad Sci USA. 107:21737–21742. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yin Y, Castro AM, Hoekstra M, Yan TJ,
Kanakamedala AC, Dehner LP, Hill DA and Ornitz DM: Fibroblast
growth factor 9 regulation by MicroRNAs controls lung development
and links DICER1 loss to the pathogenesis of pleuropulmonary
blastoma. PLoS Genet. 11(e1005242)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang
K, Wagar N, Yoon Y, Cho HT, Scala S and Shim H: Involvement of
miR-326 in chemotherapy resistance of breast cancer through
modulating expression of multidrug resistance-associated protein 1.
Biochem Pharmacol. 79:817–824. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Modi S and Seidman AD: Single-agent
gemcitabine in the treatment of advanced breast cancer. Clin Breast
Cancer. 4 (Suppl 3):S101–S106. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yin Y, Wang F and Ornitz DM: Mesothelial-
and epithelial-derived FGF9 have distinct functions in the
regulation of lung development. Development. 138:3169–3177.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schwartz DR, Wu R, Kardia SL, Levin AM,
Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, et
al: Novel candidate targets of beta-catenin/T-cell factor signaling
identified by gene expression profiling of ovarian endometrioid
adenocarcinomas. Cancer Res. 63:2913–2922. 2003.PubMed/NCBI
|
|
27
|
Parvizpour S, Razmara J and Omidi Y:
Breast cancer vaccination comes to age: Impacts of bioinformatics.
Bioimpacts. 3:223–235. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shabnam B, Padmavathi G, Banik K, Girisa
S, Monisha J, Sethi G, Fan L, Wang L, Mao X and Kunnumakkara AB:
Sorcin a potential molecular target for cancer therapy. Transl
Oncol. 11:1379–1389. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Temian DC, Pop LA, Irimie AI and
Berindan-Neagoe I: The epigenetics of triple-negative and
basal-like breast cancer: Current knowledge. J Breast Cancer.
21:233–243. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gasparini P, Cascione L, Fassan M, Lovat
F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and
Huebner K: MicroRNA expression profiling identifies a four microRNA
signature as a novel diagnostic and prognostic biomarker in triple
negative breast cancers. Oncotarget. 5:1174–1184. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kumaraswamy E, Wendt KL, Augustine LA,
Stecklein SR, Sibala EC, Li D, Gunewardena S and Jensen RA: BRCA1
regulation of epidermal growth factor receptor (EGFR) expression in
human breast cancer cells involves microRNA-146a and is critical
for its tumor suppressor function. Oncogene. 34:4333–4346.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Humphries B, Wang Z, Oom AL, Fisher T, Tan
D, Cui Y, Jiang Y and Yang C: MicroRNA-200b targets protein kinase
Cɑ and suppresses triple-negative breast cancer metastasis.
Carcinogenesis. 35:2254–2263. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tsouko E, Wang J, Frigo DE, Aydoğdu E and
Williams C: MiR-200a inhibits migration of triple-negative breast
cancer cells through direct repression of the EPHA2 oncogene.
Carcinogenesis. 36:1051–1060. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Blower PE, Chung JH, Verducci JS, Lin S,
Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et
al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol
Cancer Ther. 7:1–9. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gottesman MM, Lav O, Hall MD and Gillet
JP: Toward a better understanding of the complexity of cancer drug
resistance. Annu Rev Pharmacol Toxicol. 56:85–102. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chen J, Tian W, Cai H, He H and Deng Y:
Down-regulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pogribny IP, Filkowski JN, Tryndyak VP,
Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs
and their targets are associated with acquired resistance of MCF-7
breast cancer cells to cisplatin. Int J Cancer. 127:1785–1794.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Casanova-Salas I, Rubio-Briones J,
Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A,
Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of
miR-187 and miR-182 as biomarkers of early diagnosis and prognosis
in patients with prostate cancer treated with radical
prostatectomy. J Urol. 192:252–259. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang QL, Wang W, Li J, Tian SY and Zhang
TZ: Decreased miR-187 induces retinal ganglion cell apoptosis
through upregulating SMAD7 in glaucoma. Biomed Pharm Ther.
75:19–25. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Locke JM, da Silva Xavier G, Dawe HR,
Rutter GA and Harries LW: Increased expression of miR-187 in human
islets from individuals with type 2 diabetes is associated with
reduced glucose-stimulated insulin secretion. Diabetologia.
57:122–128. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Barton-Burke M: Gemcitabine: A
pharmacologic and clinical overview. Cancer Nurs. 22:176–183.
1999.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dyawanapelly S, Kumar A and Chourasia MK:
Lessons learned from gemcitabine: Impact of therapeutic carrier
systems and gemcitabine's drug conjugates on cancer therapy. Crit
Rev Ther Drug Carrier Syst. 1:63–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chaudhari U, Nemade H, Gaspar JA,
Hescheler J, Hengstler JG and Sachinidis A: MicroRNAs as early
toxicity signatures of doxorubicin in human-induced pluripotent
stem cell-derived cardiomyocytes. Arch Toxicol. 90:3087–3098.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang S, Kou Y, Hu C and Han Y: MicroRNA
profiling in the dentate gyrus in epileptic rats: The role of
miR-187-3p. Medicine (Baltimore). 96(e6744)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362.
2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Abdel-Rahman WM, Kalinina J, Shoman S,
Eissa S, Ollikainen M, Elomaa O, Eliseenkova AV, Bützow R,
Mohammadi M and Peltomäki P: Somatic FGF9 mutations in colorectal
and endometrial carcinomas associated with membranous β-catenin.
Hum Mutat. 29:390–397. 2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Galluzzi L, Spranger S, Fuchs E and
López-Soto A: WNT signaling in cancer immunosurveillance. Trends
Cell Biol. 18:30143–30150. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Shi S, Chen X, Liu H, Yu K, Bao Y, Chai J,
Gao H and Zou L: LGR5 acts as a target of miR-340-5p in the
suppression of cell progression and drug resistance in breast
cancer via Wnt/β-catenin pathway. Gene. 18:31039–31044.
2018.PubMed/NCBI View Article : Google Scholar
|
